Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer(NEOCAP):A single-arm,open-label,phase 2 study
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer(NEOCAP):A single-arm,open-label,phase 2 study